NEW YORK (GenomeWeb) — The US Securities and Exchange Commission today charged Bruker with violating the Foreign Corrupt Practices Act.

The SEC charged that the Billerica, Mass.-based company provided non-business related travel and improper payments to Chinese government officials in an effort to win business.

Bruker has agreed to pay approximately $2.4 million to settle the charges, including $1,714,852 in disgorgement, $310,117 in prejudgment interest, and a $375,000 penalty.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A former Synthetic Genomics attorney alleges that the firm discriminated against her and other female employees, according to the San Diego Union-Tribune.

Due to privacy and lab certification questions, the planned giveaway of Orig3n testing kits at a Baltimore Ravens game was suspended.

Alnylam reports positive results from its phase 3 clinical trial of an RNAi-based drug, according to Stat News.

In Cell this week: adult mesenchymal cell populations in mouse lung, genetic diversity in HPV16 and cancer risk protection, and more.